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favorable cytogenetic group had the expected longer sur-
vival when given chemotherapy + GO rather than
chemotherapy alone. The Southwest Oncology Group
has also failed to notice an effect of CD33 SNPs on out-
come in adults (M Othus, 2018, personal communication). 
Even the minority of patients who benefit from GO
might benefit more from development of improved anti-
CD33 therapeutics.17 One possibility here is use of bispe-
cific antibodies (BiAbs) that engage CD33 but also direct
T cells toward AML cells. An obvious model for this
approach is blinatumomab,18 a CD3/CD19 molecule built
in the Bispecific T-cell Engager (BiTE) format. A first series
of CD33/CD3 BiAbs, including the BiTE AMG 330 and
the tandem diabody AMV-564, have recently entered clin-
ical tests. 
Like GO, all CD33 BiAbs (and other CD33-directed
therapeutics) currently under investigation recognize the
V set domain, which is located distally on CD33.
However, preliminary studies with artificial CD33 mole-
cules show that membrane proximal binding enhances
the immune effector cell functions of CD33 antibodies (R
Walter, 2018, personal communication). Development of
antibodies recognizing such proximal sites is likely to be
an area of examination in GO’s second and, hopefully,
subsequent acts. 
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The clinical activity of lenalidomide in chronic lym-phocytic leukemia (CLL) was first reported morethan 10 years ago.1,2 Since then, this agent has been
studied in various combinations with anti-CD20 mono-
clonal antibodies, chemotherapy, chemo-immunotherapy
and B-cell receptor (BCR)-targeting agents. These studies
have shown clinical responses; however, most importantly,
they have also highlighted unique and unexpected toxici-
ties, in particular when lenalidomide was combined with
chemo-immunotherapy and targeted agents.
In this issue of Haematologica, Kater and colleagues report
the experience of the HOVON CLL study group on the fea-
sibility and efficacy of the combination of lenalidomide,
chlorambucil, and rituximab in treatment-naïve patients
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with CLL.3 The patients enrolled in this trial were consid-
ered ineligible to receive the combination of fludarabine,
cyclophosphamide, and rituximab (FCR) because of their
older age or the presence of comorbidities. For the first six
cycles (induction-I), lenalidomide was given in combination
with chlorambucil and rituximab at a starting dose of 2.5
mg, with escalation to 10 mg. The authors report that they
were able to administer a median lenalidomide dose of
86.7% of the full dose, with the full dose given to more
than 50% of patients. For the next six cycles (induction-II),
lenalidomide was given as monotherapy at a dose of 10 mg
daily. The median administered dose was 99.7% of the full
dose, and the full dose was given to 69% of patients during
cycle 6. The results of this phase 1-2 study showed that the
combination of lenolidamide, chlorambucil, and rituximab
can be safely administered to patients with CLL: grade 3-4
toxicities were mainly hematologic (grade 3-4 neutropenia
occurred in 73% and 64% of patients during induction-I
and induction-II, respectively), tumor lysis syndrome did
not occur, tumor flare reaction occurred in five (9%)
patients (mainly grade 2), and two (4%) patients had a
thromboembolic event despite thromboembolic prophy-
laxis. Of 53 patients in induction-I, eight discontinued treat-
ment because of excessive toxicity, whereas five of 42
patients discontinued treatment during induction-II. The
authors also report on the activity of this combination:
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Figure 1. Mechanisms of
action of lenalidomide. The
mechanisms of action of
lenalidomide include: (A)
direct effects on CLL cells
and (B, C) modification of
tumor-microenvironment
interactions. This figure is
reproduced with permission
from Mattei R et al.,
Lenalidomide in chronic lym-
phocytic leukemia: the pres-
ent and future in the era of
tyrosine kinase inhibitors.







responses were seen in 83% of the patients treated, the
median progression-free survival was 49 months, and the 3-
year overall survival rate was 95%.
Early monotherapy trials showed that lenalidomide is
associated with a unique toxicity profile in patients with
CLL, causing tumor lysis syndrome, tumor flare reaction,
myelosuppression, and, in particular, neutropenia, skin
rash, and diarrhea.1,2 Particularly severe events, including
deaths, were reported in trials with no dose escalation4 or
rapid dose escalation,5 and tumor lysis syndrome occurred
in patients with bulky lymphadenopathy despite proper
prophylaxis.1 After these early experiences, trials with
lenalidomide employed stepwise dose escalation strategies
with low starting doses (usually 2.5 mg/day), as in the study
presented by Kater et al., and managed tumor flare reactions
with non-steroidal anti-inflammatory drugs and corticos-
teroids. Moreover, careful patient selection is recommend-
ed. The population included in the study by Kater et al.
mainly consisted of older but fit patients: 98% were 65
years or older, 87% had a Cumulative Illness Rating Scale
score of 6 or lower, and all had a glomerular filtration rate
of 60 mL/min or higher at the time of entry into the study.
In the last decade, several lenalidomide-containing com-
bination regimens have been evaluated in patients with
treatment-naïve CLL. When lenalidomide was combined
with rituximab in the frontline setting, the treatment was
generally well tolerated, with the most common grade 3-4
toxicities being neutropenia, anemia, infections, increased
transaminase levels, and skin rash.6,7 However, when differ-
ent partners, such as chemotherapy agents or targeted
drugs, were tested in combination with lenalidomide, some
trials documented excessive toxicities that led to early ter-
mination of the studies. For instance, a phase 1 study inves-
tigating the combination of lenalidomide with fludarabine
and rituximab was closed early because of unpredictable
reactions and unexpectedly persistent myelosuppression,
even when very low doses of fludarabine and lenalidomide
were given, which made treatment delivery difficult.8
Instead, induction treatment with low-dose lenalidomide
together with reduced-dose FCR was demonstrated to be
safe.9 In the relapse setting, lenalidomide was evaluated in
association with rituximab and ibrutinib; the study investi-
gating this approach showed a high incidence of persistent
severe neutropenia that occurred despite growth factor sup-
port.10 This unfavorable toxicity profile, together with poor
preliminary efficacy data, discouraged further evaluation of
this combination. The combination of lenalidomide with
rituximab and idelalisib also showed unacceptable liver tox-
icity in patients with relapsed or refractory indolent lym-
phoma.11
Regarding efficacy, the single-arm design of the study by
Kater et al. does not allow a direct comparison of the triple
combination with chlorambucil and rituximab.
Acknowledging the limitations of cross-trial comparisons,
however, the efficacy of the proposed regimen compares
positively with that of chlorambucil plus anti-CD20 mono-
clonal antibodies. In a study conducted by Strati et al.,7 the
combination of lenalidomide plus rituximab produced an
overall response rate of 73% in treatment-naïve patients,
with a complete remission (CR)/CR with incomplete hema-
tologic recovery (CRi) rate of 35%, a median time to treat-
ment failure of 22 months, and a 4-year overall survival rate
of 90%. The same treatment combination was explored in
a multicenter study, which showed an overall response rate
of 88%, of which 15% were CR/CRi, and a median pro-
gression-free survival of 19 months.6
It is essential to put the data presented by Kater and col-
leagues into perspective by considering recent changes in
the treatment landscape of CLL brought about by the avail-
ability of new targeted drugs, such as BTK inhibitors, PI3K
inhibitors, and Bcl-2 antagonists, which have also been
studied in older patients. In a recent update of the phase III
RESONATE-2 trial of ibrutinib, which enrolled patients
aged 65 years and older with previously untreated CLL and
without del(17p), researchers reported that at a median fol-
low-up time of 29 months, the overall response rate was
92%, the median duration of progression-free survival had
not been reached, and the 24-month progression-free sur-
vival rate was 89%.12 Patients carrying abnormalities on
chromosome 17 represent a subset of CLL patients with a
particularly poor prognosis. In the cohort presented by
Kater et al., eight (17%) patients had del(17p), and their pro-
gression-free survival rate was lower than that of patients
without del(17p) (38% versus 59% at 3 years). Notably, in a
phase II study that evaluated ibrutinib in a cohort of treat-
ment-naïve CLL patients with TP53 aberrations, the esti-
mated 5-year progression-free survival rate was 74.4%.13
That being said, a credit that pertains exclusively to
lenalidomide is the role this drug has had in elucidating
tumor-microenvironment interactions in CLL. Phenotypic
and functional immune defects are known to be associated
with CLL; these defects confer an increased risk of infec-
tions and autoimmune phenomena and foster leukemia cell
proliferation and survival. Several studies have shown that
treatment with lenalidomide modulates the cross-talk
between tumor cells and various components of the tumor
microenvironment. Examples of these effects include the
ability to normalize CD3+ T-cell and Treg numbers in vivo14,15
and to restore immunological synapse formation.16 The
antitumoral activities of lenalidomide also appear to be
attributable to a direct effect on neoplastic cells; lenalido-
mide not only enhances immune recognition, but also
induces CRBN-mediated upregulation of p21 in vitro17
(Figure 1). 
The recent progresses in immunotherapy approaches
that exploit the ability to engineer the T-cell receptor, such
as chimeric antigen receptor (CAR) T-cell therapy, may revi-
talize interest in the use of immunomodulatory agents,
including lenalidomide, in CLL. Immune dysfunctions are
thought to be responsible for the lower efficacy of these
approaches in CLL than in other lymphoproliferative dis-
eases. Apheresis products from CLL patients and the
derived CAR T-cell products exhibit an exhausted pheno-
type and tend to have reduced potency. It has been demon-
strated that certain features of the apheresis product, such
as the predominance of early memory/naïve T cells and
low expression of exhaustion markers, correlate with effi-
cacy.18 It has also been reported that ibrutinib may correct
some of the T-cell defects that hinder CAR T-cell produc-
tion and enhance in vivo function.19 The ability of lenalido-
mide to enhance CAR T-cell activity has been explored in a
mouse model of B-cell lymphoma20 and provides a rationale
for future investigations of the immunomodulatory proper-
ties of lenalidomide and its derivatives in CLL. 
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